Announced that the U.S. Food and Drug Administration has granted Fast Track Designation to pelareorep ...
Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a difficult-to-treat population Company to launch controlled study in second-line KRAS-mutant...
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The global oncology market is surging toward $668.26 billion by 2034 with an 11.50% CAGR as innovative...
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The global oncology market is charging toward a massive $668 billion valuation by 2034[1], fueled by a...
Today announced the voting results from its Special Meeting of Shareholders held on Thursday, January ...
SAN DIEGO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“ Oncolytics ” or the “ Company ”), a clinical-stage immunotherapy company developing pelareorep, today...
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The genomics in cancer care market is on a massive tear, projected to hit $69.16 billion by 2032 as doctors...
SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced...
Announced updated clinical data from GOBLET Cohort 4 in patients with third-line metastatic squamous ...
Compared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR Combination achieved encouraging median DOR of almost 17 months Data establishes clear path in indication with...